These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4724706)

  • 1. Effect of growth hormone and thyroxine on the contractile properties of dystrophic muscle.
    Berk SL; Ullrick WC
    Experientia; 1973; 29(7):809-10. PubMed ID: 4724706
    [No Abstract]   [Full Text] [Related]  

  • 2. Human growth hormone and estrogens in boys with Duchenne muscular dystrophy.
    Chyatte SB; Rudman D; Patterson JH; Gerron GG; O'Beirne I; Barlow J; Jordan A; Shavin JS
    Arch Phys Med Rehabil; 1973 Jun; 54(6):248-53. PubMed ID: 4708006
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment problems using anabolic steroids in progressive muscular dystrophy].
    Badalian LO; Temin PA; Mukhin KIu
    Klin Med (Mosk); 1984 Nov; 62(11):23-9. PubMed ID: 6394898
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of growth hormone and thyroxinon isometric contractile mechanics of cardiac muscle.
    Minelli R; Korecky B
    Can J Physiol Pharmacol; 1969 Jun; 47(6):545-52. PubMed ID: 5797395
    [No Abstract]   [Full Text] [Related]  

  • 5. Abnormal polyamine metabolism in hereditary muscular dystrophies: effect of human growth hormone.
    Rudman D; Kutner MH; Chawla RK; Goldsmith MA
    J Clin Invest; 1980 Jan; 65(1):95-102. PubMed ID: 7350201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contractile properties of skeletal muscle in dystrophic mice.
    Taylor RG; Fowler WM; Mason DT; Spann JF
    Arch Phys Med Rehabil; 1971 Nov; 52(11):511-5. PubMed ID: 5121040
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyper-responsiveness of patients with limb-girdle dystrophy to human growth hormone.
    Rudman D; Chyatte SB; Gerron GG; O'Beirne I; Barlow J
    J Clin Endocrinol Metab; 1972 Aug; 35(2):256-60. PubMed ID: 5072356
    [No Abstract]   [Full Text] [Related]  

  • 8. Muscle diseases: the muscular dystrophies.
    McNally EM; Pytel P
    Annu Rev Pathol; 2007; 2():87-109. PubMed ID: 18039094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tropomyosin and troponin in normal and dystrophic human muscle.
    Samaha FJ
    Arch Neurol; 1972 Jun; 26(6):547-50. PubMed ID: 5030788
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of growth hormone and thyroxine on growth and chemical composition of muscle, bone and other tissues in thyroidectomized-hypophysectomized rats.
    SCOW RO
    Am J Physiol; 1959 Apr; 196(4):859-65. PubMed ID: 13637230
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of denervation on normal and dystrophic muscle: DNA and nucleotide enzymes.
    McCaman MW; McCaman RE
    Am J Physiol; 1965 Sep; 209(3):495-500. PubMed ID: 4220896
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
    Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
    Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine aminopeptidase activity in muscles of dystrophic mice.
    Bois P
    Experientia; 1964 Mar; 20(3):140-1. PubMed ID: 5853679
    [No Abstract]   [Full Text] [Related]  

  • 14. Muscle wasting in muscular dystrophy: decreased protein synthesis or increased degradation?
    Griggs RC; Rennie MJ
    Ann Neurol; 1983 Feb; 13(2):125-32. PubMed ID: 6338807
    [No Abstract]   [Full Text] [Related]  

  • 15. Observations on the efficiency of dystrophic muscle in vitro.
    Hofmann WW; Ruprecht EO
    J Neurol Neurosurg Psychiatry; 1973 Aug; 36(4):565-73. PubMed ID: 4731327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agents which affect excitation-contraction coupling in normal and dystrophic muscle.
    Brust M
    Fed Proc; 1969; 28(5):1649-56. PubMed ID: 5817975
    [No Abstract]   [Full Text] [Related]  

  • 17. Force impairment in calpain 3-deficient mice is not correlated with mechanical disruption.
    Fougerousse F; Gonin P; Durand M; Richard I; Raymackers JM
    Muscle Nerve; 2003 May; 27(5):616-23. PubMed ID: 12707983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NADH-2 cytochrome C reductase and cytochrome C oxidase in experimental muscle disorders.
    Dobson HL; Kasahara M
    Tex Rep Biol Med; 1964 Dec; 22():Suppl 1:890+. PubMed ID: 4284089
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage.
    Gehrig SM; Ryall JG; Schertzer JD; Lynch GS
    Exp Physiol; 2008 Nov; 93(11):1190-8. PubMed ID: 18567600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative proteomic analysis of the contractile-protein-depleted fraction from normal versus dystrophic skeletal muscle.
    Carberry S; Zweyer M; Swandulla D; Ohlendieck K
    Anal Biochem; 2014 Feb; 446():108-15. PubMed ID: 23954569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.